However, since melanoma does not have a highly specific high expression similar to CD19 in B-cell lymphoma and the commonly selected specific receptors are also partially distributed in other tissues, the selection of targeting ligands is still not highly convincing. The gene discussed is CD19; the disease is melanoma.